



Our STN: BL 125163/670

**SUPPLEMENT APPROVAL**

July 13, 2023

ID Biomedical Corporation of Quebec  
Attention: Mariana Machado  
14200 Shady Grove Road, VR1500  
Rockville, MD 20850

Dear Ms. Machado:

Please refer to your supplement to your Biologics License Application (BLA) received March 7, 2023, submitted under section 351(a) of the Public Health Service Act (PHS Act) for Influenza Vaccine (FluLaval).

We also refer to our supplement approval letter dated June 30, 2023, which contained the following error:

(b) (4) (d/b/a GSK Vaccines) was not included in the list of manufacturing sites for Flulaval Quadrivalent.

This replacement approval letter incorporates the correction of the error. The effective approval date will remain June 30, 2023, the date of the original supplement approval letter.

We have approved your request received March 7, 2023, to supplement your Biologics License Application (BLA) submitted under section 351(a) of the Public Health Service Act for Influenza Vaccine, for FluLaval Quadrivalent manufactured at GlaxoSmithKline Vaccines (Quebec, Canada; (b) (4) and at GSK (b) (4), to include the 2023-2024 United States formulation and the associated labeling revisions.

## **LABELING**

We hereby approve the draft content of labeling: Package Insert submitted March 7, 2023, the draft carton labels submitted March 7, 2023, and the container labels submitted under Amendment 1, dated May 5, 2023.

## **CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, please submit the final content of labeling (21 CFR 601.14) in Structured Product Labeling (SPL) format via the FDA automated drug registration and listing system, (eLIST) as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the Package Insert submitted on

March 7, 2023. Information on submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As* at <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible via publicly available labeling repositories.

## **CARTON AND CONTAINER LABELS**

Please electronically submit final printed carton and container labels identical to the carton labels submitted on March 7, 2023, and container labels submitted on May 5, 2023, according to the guidance for industry *Providing Regulatory Submissions in Electronic Format — Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications* at <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/providing-regulatory-submissions-electronic-format-certain-human-pharmaceutical-product-applications>.

All final labeling should be submitted as Product Correspondence to this BLA, STN BL 125163 at the time of use and include implementation information on Form FDA 356h.

## **ADVERTISING AND PROMOTIONAL LABELING**

You may submit two draft copies of the proposed introductory advertising and promotional labeling with Form FDA 2253 to the Advertising and Promotional Labeling Branch at the following address:

Food and Drug Administration  
Center for Biologics Evaluation and Research  
Document Control Center  
10903 New Hampshire Ave.  
WO71–G112  
Silver Spring, MD 20993-0002

You must submit copies of your final advertising and promotional labeling at the time of initial dissemination or publication, accompanied by Form FDA 2253 (21 CFR 601.12(f)(4)).

All promotional claims must be consistent with and not contrary to approved labeling. You should not make a comparative promotional claim or claim of superiority over other products unless you have substantial evidence or substantial clinical experience to support such claims (21 CFR 202.1(e)(6)).

Please submit an amendment to all pending supplemental applications for this BLA that include revised labeling incorporating a revised content of labeling that includes these changes.

We will include the information contained in the above-referenced supplement in your BLA file.

Sincerely,

Jerry P. Weir, Ph.D.  
Director  
Division of Viral Products  
Office of Vaccines  
Research and Review  
Center for Biologics  
Evaluation and Research